BDR Pharma launches anti-cancer drug Furmecil
Furmecil is an oral drug, indicated in adults for the treatment of advanced gastric cancer
BDR Pharma has launched the first-in-India generic – Furmecil (known as S-1 which is a combination of three drugs – Tegafur, Gimeracil and Oteracil). Furmecil is an oral drug, indicated in adults for the treatment of advanced gastric cancer, which has demonstrated high effectiveness with a favourable safety profile, BDR Pharma informed in a statement.
Furmecil is soon going to be available in the Indian market in the form of capsules in two strengths (Tegafur 15 mg + Gimeracil 4.35 mg + Oteracil 11.80 mg and Tegafur 20 mg + Gimeracil 5.80 mg + Oteracil 15.80 mg), the statement said.
Commenting on the launch, Raheel Shah, Director, Business Development, BDR Pharma, said in the statement, “Our vision is to bring globally available and highly effective, but expensive medicines to the Indian patients making them accessible at affordable prices. BDR Pharma takes the lead to bring cost-effective treatment for gastric cancer in India as part of its latest pharma innovation. Our focussed launch of such first time ever newly advanced molecule in treatment of various cancer indications, is testimony to our solid commitment to providing access to affordable medicines for Indian cancer patients with high-quality standards without compromising patients’ safety.”